Nivolumab biosimilar(Sandoz)

纳武利尤单抗生物类似药（Sandoz）

Report date: 2026/02/25 20:02:36

Base Information

Drug NameNivolumab biosimilar(Sandoz)
Drug Alias NameJPB898JPB-898
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandPortugalPhilippines +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSandoz
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A